Old and new anticoagulants

Hamostaseologie

Volumn 31, Issue 1, 2011, Pages 21-27

  Harbrecht, Ursula ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Clinical trials; Direct oral thrombin inhibitors; Factor Xa inhibitors; Heparins; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN DERIVATIVE; DABIGATRAN; ENOXAPARIN; HEPARIN; PHENPROCOUMON; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; INTERNATIONAL NORMALIZED RATIO; PATIENT MONITORING; REVIEW; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION;

ANTICOAGULANTS; COUMARINS; HEPARIN; HUMANS; THROMBOSIS; VITAMIN K;

EID: 79952571661     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1149     Document Type: Review

References (52)

1. Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
2. Ansell J, Hirsh , Hylek E et al. Pharmacology and management of the vitamin K antagonists. Chest 2008; 133: 160S-198S.
3. Weitz JI. Low-molecular-weight heparins. New Engl J Med 1997; 337: 688-98. (Pubitemid 27375477)
4. Rost S, Fregin A, Ivascevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541. (Pubitemid 38209110)
5. Li T, Chang CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-544. (Pubitemid 38209111)
6. Poller L. INR-calibration of the therapeutic range. Adv Exp Med Biol 1987; 214: 95-112.
7. Heneghan C, Alonso-Coello P, Grarcia-Alamino JM. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-411. (Pubitemid 43184260)
8. Sconce EA, Khahn TI, Wynne HA et al. The impact of CYP2C9 and VKOR1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333. (Pubitemid 41510803)
9. Oldenburg J, Bevans CG, Fregin A et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578. (Pubitemid 47421551)
10. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; Suppl 1: 60-64.
11. Keisu M, Andersson TB. Drug induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010; 196: 407-418.
12. European Medicines Agency (2008) CHMP assessment report for Pradaxa, INN dabigatran etexilate. Procedure No. EMEA/H/C/829. Doc.Ref.: EMEA/174363/2008 (www.ema.europa.eu).
13. Eisert WG, Hauel N, Stangier W et al. Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-1889.
14. Prandoni P, Tormene D, Perlati M et al. . Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 2008; 17: 773-777. (Pubitemid 351843619)
15. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001; 58 Suppl 2: S14-S17. (Pubitemid 33027571)
16. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin fort he prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Int Med 2002; 162: 1833-1840.
17. European Medicines Agency (2008) CHMP assessment report for Xarelto, INN rivaroxaban. Procedure No. EMEA/H/C/000944. Doc.Ref.: EMEA/543519/2008 (www.ema.europa.eu).
18. Perzborn E, Roehrig S, Straub A et al. Rivaroxaban: A new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30: 376-381.
19. Lindhoff-Last E, Samama MM, Ortel TL et al. Assay for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679.
20. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009: 37: 74-81.
21. 14C-labeled apixaban in mice, rats, rabbits dogs, and humans. Drug Metab Dispos 2009; 37: 1738-1748.
22. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20.
23. Furugohri T, Isobe K, Honda Y et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542-1549.
24. Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharm 2010; 50: 743-753.
25. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double- blind, non-inferiority trial. Lancet 2007; 370: 949-956. (Pubitemid 47393577)
26. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185. (Pubitemid 47617868)
27. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthro plasty 2009; 24: 1-9.
28. Friedmann RJ, Dahl OE, Rosencher N et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010 126: 175-182.
29. Eriksson BI, Borris LC, Friedmann RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775. (Pubitemid 351930851)
30. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin fort he prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
31. Lassen MR, Ageno W, Borris LC et al. Rivroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786. (Pubitemid 351930852)
32. Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
33. Turpie AG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2010; 105. DOI: 10.1160/TH10-09-0601.
34. Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran and rivaroxaban for thromboprophylaxis after hip or knee arthroplasty. Circ Cardiovac Qual Outcomes 2010; 3: 652-660.
35. Lassen MR, Raskob GE, Gallus A et al. ADVANCE-2 investigators: Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010; 375: 807-815.
36. Huang J, Cao Y, Liao C et al. Apixaban versus enoxaparin in patients with total knee arthroplasy. A meta-analysis of randomised trials. Thromb Haemost 2010; 105: DOI 10.1160/TH10-08-0552.
37. Website: http//clinicaltrials.gov/ct2/NCT00457002
38. Website: http//clinicaltrials.gov/ct2/NCT01181102
39. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the tratment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
40. http//clinicaltrials.gov/ct2/NCT00329238
41. http//clinicaltrials.gov/ct2/NCT00558259
42. http//clinicaltrials.gov/ct2/NTC00440193; NCT00439777; NCT00439725
43. Botticelli investigators, Writing Committee; Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
44. http//clinicaltrials.gov/ct2/NCT00986154
45. http//clinicaltrials.gov/ct2/NCT00621855
46. http//clinicaltrials.gov/ct2/NCT00809965
47. http//clinicaltrials.gov/ct2/NCT00831441
48. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
49. ROCKET-AF Study Investigators: Rivaroxabanonce daily, oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.
50. Lopes RD, Alexander JH, Al-Khatib SM et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-339.
51. Eikelboom JW, O'Donnell M, Yusuf S et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-353.
52. Ruff CT, Guigliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635-641.